LEADER 04551nam 2200649 450 001 9910826442503321 005 20230807204345.0 010 $a0-19-165140-0 010 $a0-19-180182-8 010 $a0-19-165139-7 035 $a(CKB)2670000000571672 035 $a(EBL)1816432 035 $a(OCoLC)893653925 035 $a(SSID)ssj0001411744 035 $a(PQKBManifestationID)11803957 035 $a(PQKBTitleCode)TC0001411744 035 $a(PQKBWorkID)11401599 035 $a(PQKB)10155949 035 $a(MiAaPQ)EBC1816432 035 $a(StDuBDS)EDZ0001098136 035 $a(Au-PeEL)EBL1816432 035 $a(CaPaEBR)ebr10954059 035 $a(CaONFJC)MIL651923 035 $a(EXLCZ)992670000000571672 100 $a20141021h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aImaging in neurodegenerative disorders /$fedited by Luca Saba 205 $aFirst edition. 210 1$aOxfordshire, [England] :$cOxford University Press,$d2015. 210 4$dİ2015 215 $a1 online resource (585 p.) 300 $aDescription based upon print version of record. 311 $a0-19-967161-3 311 $a1-322-20643-0 320 $aIncludes bibliographical references and index at the end of each chapters. 327 $aCover; Imaging in Neurodegenerative Disorders; Copyright; Dedication; Contents; List of abbreviations; List of contributors; SECTION 1 Introduction; 1 Epidemiology of neurodegenerative diseases; 2 Metabolomics of neurodegenerative disorders; 3 Transcriptome profiling in neurodegenerative disorders; 4 Health economic considerations in neurodegenerative disorders; 5 Symptoms of neurodegenerative diseases; SECTION 2 Imaging technique; 6 Computed tomography; 7 General principles of magnetic resonance imaging; 8 Nuclear medicine and radiology; 9 Molecular imaging and neurodegenerative disorders 327 $a10 Positron emission tomography in neurodegenerative disorders-evolving techniques and new tracers11 Radiopharmaceuticals for molecular imaging of neurodegenerative diseases; SECTION 3 Neurodegeneration: cognition; 12 Neuroimaging of Alzheimer's disease; 13 MRI-based imaging of Alzheimer's disease; 14 Frontotemporal dementia; 15 Dementia with Lewy bodies; 16 Corticobasal syndrome and corticobasal degeneration; SECTION 4 Neurodegeneration: movement; 17 Parkinson's disease: clinical and imaging features; 18 Progressive supranuclear palsy; 19 Imaging in Huntington's disease 327 $a20 Multiple system atrophy21 Clinical benefit of dopamine transporter imaging in movement disorders and dementia; SECTION 5 Neurodegeneration: strength; 22 Amyotrophic lateral sclerosis; SECTION 6 Neurodegeneration: coordination; 23 Spinocerebellar atrophies; 24 Imaging in Friedreich's ataxia; 25 Neuroimaging in human prion diseases; SECTION 7 Neurodegeneration: peripheral and autonomic nervous systems; 26 Amyloidosis; 27 Neurodegeneration: metabolic and toxin-related disorders; SECTION 8 Neurodegeneration: myelin; 28 Demyelinating diseases; 29 Charcot-Marie-Tooth disease 327 $a30 Neurodegenerative disorders of the basal gangliaSECTION 9 Neurodegeneration: trauma; 31 Neurodegeneration post trauma: brain; 32 Neurodegeneration post trauma: spine; 33 Neurodegeneration after trauma: peripheral nerves; SECTION 10 Neuroimaging after therapy; 34 Functional imaging of neurosurgery in Parkinson's disease; 35 Neuroimaging after cell-based therapy; Index 330 $aDiagnosing neurodegenerative diseases can prove particularly intimidating to clinicians, because many times the diagnosis cannot be critically ""confirmed"" by a simple test. New imaging modalities have advanced to the point of high resolution, morphological, metabolic and functional analysis. Computed tomography, magnetic resonance, nuclear medicine and molecular imaging have recently emerged as outstanding non-invasive techniques for the study of theneurodegenerative disorders. Imaging in Neurodegenerative Disorders covers all the imaging techniques and new exciting methods like new tracers, 606 $aNervous system$xDegeneration 606 $aBrain$xDegeneration 615 0$aNervous system$xDegeneration. 615 0$aBrain$xDegeneration. 676 $a616.8047 702 $aSaba$b Luca 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910826442503321 996 $aImaging in neurodegenerative disorders$94083240 997 $aUNINA